Yao-Guang Huang

Rational design of chromeno[8,7-d]oxazoles as CDK16-directed inhibitors with improved solubility and antitumor activity.

Acquired resistance to established molecularly targeted therapies remains a major challenge in non-small cell lung cancer (NSCLC). In this study, a series of chromeno[8,7-d]oxazole derivatives was designed from the CDK9-preferring hit HS-36 through structure-guided modification of the C-8 side chain and N-1 substituent...